Testing for antineutrophil cytoplasmic antibodies

Expert Review of Molecular Diagnostics

Volumn 1, Issue 3, 2001, Pages 281-289

  Savige, Judy ^a  

^a AUSTIN HEALTH   (Australia)

Author keywords

Antineutrophil cytoplasmic antibodies; Mocroscopic polyangiitis; Myeloperoxidase; Proteinase 3; Vasculicis; Wegeni's granulomatosis

Indexed keywords

NEUTROPHIL CYTOPLASMIC ANTIBODY;

ANTIGEN SPECIFICITY; DIAGNOSTIC TEST; DISEASE CLASSIFICATION; IMMUNOFLUORESCENCE; INFLAMMATION; REVIEW; VASCULITIS; WEGENER GRANULOMATOSIS;

EID: 0035558475     PISSN: 14737140     EISSN: None     Source Type: Journal    
DOI: 10.1586/14737159.1.3.281     Document Type: Review

References (68)

1. Antineutrophil cytoplasmic antibodies and associated diseases: A review of the clinical and laboratory features
2. Antiproteinase 3 and antimyeloperoxidase-associated vasculitis
3. Evolving concepts about the role of antineutrophil cytoplasm autoantibodies in systemic vasculitides
4. Segmental necrotising glomerulonephritis with antineutrophil antibody: Possible arbovirus aetiology?
5. The TH. Autoantibodies against neutrophils and monocytes: Tool for diagnosis and marker of disease activity in Wegener's granulomatosis
6. Prospective study of radioimmunoassay for antibodies against neutrophil cytoplasm in diagnosis of systemic vasculitis
7. Critical reevaluation of 41 cases of 'idiopathic' crescentic glomerulonephritis
8. Systemic vasculitis in the 1980s: Is there an increasing incidence of Wegener's granulomatosis and microscopic polyarteritis?
9. Anticytoplasmic autoantibodies in the diagnosis and follow-up of Wegener's granulomatosis
10. Wegener's granulomatosis autoantibodies identify a novel disopropylfluorophosphate-binding protein in the lysosomes of normal human neutrophils
11. Wegener's granulomatosis autoantigen is a novel neutrophil serine proteinase
12. Antineutrophil cytoplasmic autoantibodies with specificity for myeloperoxidase in patients with systemic vasculitis and idiopathic necrotising and crescentic glomerulonephritis
13. A renal biopsy is essential for the management of ANCA-positive patients with glomerulonephritis
14. Downregulation of a serine protease, myeloblastin, causes growth arrest and differentiation of promyelocytic leukemia cells
15. Proteinase 3: A distinct human polymorphonuclear leucocyte proteinase that produces emphysema in hamsters
16. Immunofluorescent patterns associated with antineutrophil cytoplasmic antibodies (ANCA) and their differentiation from other auto- and alloantibodies
17. Cytoplasmic fluorescence in a routine immunopathology laboratory
18. Circulating antielastase in systemic lupus erythematosus
19. Anti-elastase, cathepsin G and lactoferrin antibodies in sera with cANCA or with atypical fluorescence staining pattern
20. Bactericidal/permeability increasing (BPI) protein is an important antigen for antineutrophil cytoplasmic autoantibodies (ANCA) in vasculitis
21. Autoantibodies directed against lysozyme: A new target of antineutrophil cytoplasmic antibodies (ANCA)
22. Azurocidin is a novel antigen for antineutrophil cytoplasmic autoantibodies (ANCA) in systemic vasculitis
23. Differences between antimyeloperoxidaseand antiproteinase 3-associated renal disease
24. Disease spectrum of patients with antineutrophil cytoplasmic autoantibodies of defined specificity: Distinct differences between patients with antiproteinase 3 and antimyeloperoxidase autoantibodies
25. Clinical spectrum associated with ANCA of defined antigen specificities in 98 selected patients
26. ANCA predicting relapse in systemic vasculitis
27. Association between active Wegener's granulomatosis and anticytoplasmic antibodies
28. Wegener granulomatosis: An analysis of 158 patients
29. Cyclophosphamide-induced cystitis and bladder cancer in patients with Wegener's granulomatosis
30. Antitrypsin genetic polymorphism in ANCA-positive systemic vasculitis
31. The PiZ gene of α lantitrypsin as a determinant of outcome in PR3ANCA-positive vasculitis
32. Activation of granulocytes by antineutrophil cytoplasmic antibodies (ANCA) in Wegener's granulomatosis: A predominant role for the IgG 3 subclass of ANCA
33. Relevance of classic antineutrophil cytoplasmic autoantibody (C-ANCA)-mediated inhibition of proteinase 3-α 1 antitrypsin complexation to disease activity in Wegener's granulomatosis
34. α 1-antitrypsin deficiency and antiproteinase 3 antibodies in ANCA-associated systemic vasculitis
35. Active generalised Wegener's granulomatosis without ANCA - A new subset in WG?
36. ANCA positive and ANCA negative microscopic polyarteritis
37. Autoantibodies in antineutrophil cytoplasmic antibody (ANCA)-associated vasculitides
38. The coexistence of ANCA and antiGBM antibodies in patients with RPGN
39. Lupus anticoagulant in antineutrophil cytoplasmic antibodies
40. A distinct subset of antineutrophil cytoplasmic antibodies is associated with inflammatory bowel disease
41. Antineutrophil antibodies in inflammatory bowel disease: Prevalence and diagnostic role
42. Perinuclear antineutrophil cytoplasmic antibodies in patients with Crohn's disease define a clinical subgroup
43. Antineutrophil cytoplasmic autoantibody-associated diseases: A rheumatologist's perspective
44. Antineutrophil cytoplasm antibodies in rheumatoid arthritis
45. Anticytopasmic atibodies (ANCA)-associated crescentic glomerulonephritis and propylthiouracil therapy
46. Antigen specificity in hydralazine associated ANCA positive systemic vasculitis
47. A prospective study of antineutrophil cytoplasmic antibody (C-ANCA) and clinical criteria in diagnosing Wegener's granulomatosis
48. The role of antineutrophil cytoplasmic antibody (CANCA) testing in the diagnosis of Wegener's granulomatosis
49. International Consensus Statement on Testing and Reporting Antineutrophil cytoplasmic antibodies (ANCA)
50. Some patients with antimyeloperoxidase antibodies have a cANCA pattern
51. Diagnostic value of standardised assays for antineutrophil cytoplasmic antibodies in idiopathic systemic vasculitis: EC/BCR project for ANCA assay standardisation
52. Diagnostic predictive value of ANCA serology
53. Delineation of a standard procedure for indirect immunofluorescence detection of ANCA
54. Methods to detect autoantibodies to neutrophilic granulocytes
55. Detection of autoantibodies to neutrophil cytoplasmic antigens
56. Indirect immunofluorescence (IIF) of washed peripheral blood cells to demonstrate antineutrophil cytoplasmic antibodies (ANCA)
57. The Octospot cytocentrifugation system for ANCA slide production
58. Human mast cells expressing recombinant proteinase 3 (PR3) as substrate for clinical testing for antineutrophil cytoplasmic antibodies (ANCA)
59. Capture ELISA based on recombinant PR3 is sensitive for PR3-ANCA testing and allows detection of PR3 and PR3-ANCA/PR 3 immunocomplexes
60. Antibodies to recombinant myeloperoxidase in patients with necrotising crescentic glomerulonephritis (NCGN)
61. Comparison of eight commercial kits for quantitation of antineutrophil cytoplasmic antibodies (ANCA)
62. Clinical evaluation of a capture ELISA for detection of proteinase 3 antineutrophil cytoplasmic antibody
63. Antineutrophil cytoplasmic autoantibodies in Wegener's granulomatosis recognise conformational epitope(s) on proteinase 3
64. Antinative and recombinant myeloperoxidase monoclonals and human antibodies
65. Epitope mapping of antiproteinase 3 and antimyeloperoxidase antibodies
66. 'Near patient' testing for two ANCA antigens: Proteinase 3 and myeloperoxidase
67. Antibody to Saccharomyces cerevisiae mannan in Crohn's disease
68. Antisaccharomyces cerevisiae mannan antibodies combined with antineutrophil antibodies in inflammatory bowel disease: Prevalence and diagnostic role